{"id":2832,"date":"2026-08-24T23:53:57","date_gmt":"2026-08-24T23:53:57","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/it\/?post_type=product&p=2832"},"modified":"2026-08-24T23:53:58","modified_gmt":"2026-08-24T23:53:58","slug":"buy-fragment-176-191-5mg-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/it\/product\/buy-fragment-176-191-5mg-in-switzerland\/","title":{"rendered":"Fragment 176-191 (5MG)"},"content":{"rendered":"

What Is Fragment 176-191 and Why Buy It for Research?<\/strong><\/h2>\n

Buy Fragment 176-191 5mg in Switzerland for research into lipid metabolism, adipocyte signaling, and the lipolytic actions of growth hormone. Specifically, Fragment 176-191 (also known as HGH Fragment 176-191, hGH 176-191, or Growth Hormone Fragment) is a synthetic 16-amino acid peptide corresponding to the C-terminal region of human growth hormone, specifically residues 176 through 191 of the full 191-amino acid hGH molecule.<\/p>\n

The peptide sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF), with a stabilizing intramolecular disulfide bond between the two cysteine residues (Cys7-Cys14, corresponding to Cys182-Cys189 in native hGH). Professor Frank M. Ng and colleagues at Monash University, Melbourne, Australia, identified this fragment as the minimal lipolytic domain of growth hormone through systematic structure-function mapping during the early 1990s.<\/p>\n

The foundational 1993 finding demonstrated that the synthetic C-terminal peptide hGH(177-191) possessed antilipogenic activity identical to intact growth hormone when tested on isolated adipocytes, while completely lacking the growth-promoting and diabetogenic effects of the full hormone. In scientific research, Fragment 176-191 serves as a molecular tool for studying the lipolytic actions of growth hormone independently of its systemic growth effects. Furthermore, Core Peptides supplies Fragment 176-191 as a lyophilized powder in a 5mg format exclusively for laboratory use. Therefore, researchers seeking to source this compound for their work will find it readily available when they buy Fragment 176-191 5mg in Switzerland.<\/p>\n

Fragment 176-191 Research Overview: Buy Fragment 176-191 5mg in Switzerland for Lipolysis Studies<\/strong><\/h2>\n

Centrally, research into Fragment 176-191 has focused on its function as a lipolytic peptide that mimics the fat-burning effects of growth hormone without the systemic growth-promoting or insulin-desensitizing effects. Endogenously, human growth hormone stimulates lipolysis (the breakdown of stored fat into free fatty acids) and inhibits lipogenesis (the conversion of glucose into fat). Fragment 176-191 was specifically identified as the minimal C-terminal domain responsible for these metabolic effects.<\/p>\n

This C-terminal fragment regulates fat metabolism without the adverse effects on blood sugar or growth associated with full-length hGH. Studies have shown that Fragment 176-191 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (the transformation of nonfat food materials into body fat). Furthermore, Fragment 176-191 is more potent than full-length HGH in stimulating lipolysis and can inhibit the production of lipids such as fatty acids in the body. Natera, Jiang, and Ng (1994) extended these findings to in vivo models, demonstrating chronic weight loss in obese ob\/ob mice.<\/p>\n

Importantly, Fragment 176-191 works as part of HGH by mimicking the way natural HGH regulates human metabolism, but does not have adverse side effects on insulin sensitivity, blood glucose, cell proliferation, or muscle growth as whole-segment HGH. This selective action makes it a valuable research tool for studying lipid metabolism without the confounding effects of growth promotion. Accordingly, researchers who buy Fragment 176-191 5mg in Switzerland from Core Peptides can support their investigations into lipid metabolism, adipocyte signaling, and metabolic regulation.<\/p>\n

How Does Fragment 176-191 Work in Research?<\/strong><\/h2>\n

Mechanistically, Fragment 176-191’s proposed action involves functioning as a lipolytic peptide that interacts with adipocytes to modulate fat metabolism through the lipolytic domain of growth hormone.<\/p>\n

Lipolysis Stimulation<\/strong><\/h3>\n

Fragment 176-191 stimulates the breakdown of stored triglycerides into free fatty acids and glycerol\u2014a process known as lipolysis. In isolated adipocyte studies, the synthetic C-terminal peptide hGH(177-191) demonstrated antilipogenic activity identical to intact growth hormone. The peptide appears to act directly at the level of fat cells to promote the mobilization of stored lipids.<\/p>\n

Lipogenesis Inhibition<\/strong><\/h3>\n

Fragment 176-191 inhibits lipogenesis\u2014the formation of fatty acids and other lipids in the body. By blocking the conversion of nonfat food materials into body fat, the peptide helps maintain metabolic balance. This dual action\u2014stimulating fat breakdown while inhibiting fat formation\u2014makes Fragment 176-191 a focused tool for studying lipid metabolism.<\/p>\n

Selective Metabolic Action<\/strong><\/h3>\n

Unlike full-length growth hormone, Fragment 176-191 does not adversely affect insulin sensitivity or blood glucose levels. It also lacks the growth-promoting and cell-proliferative effects of intact hGH. This selectivity is thought to arise from the separation of the lipolytic domain (located in the C-terminal region) from the growth-promoting domains of the full-length hormone.<\/p>\n

Structural Features<\/strong><\/h3>\n

The peptide contains a stabilizing intramolecular disulfide bond between the two cysteine residues (Cys7-Cys14 in the fragment, corresponding to Cys182-Cys189 in native hGH). This disulfide bond establishes a loop within the C-terminal region and contributes to the peptide’s biological activity.<\/p>\n

Why Is Fragment 176-191 Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study Fragment 176-191 because it represents a well-characterized C-terminal hGH fragment that enables investigation of lipid metabolism, lipolysis, and adipocyte signaling without the complications of full-length growth hormone signaling. In fact, this peptide offers a focused tool for studying the molecular mechanisms underlying fat breakdown, fat formation inhibition, and metabolic homeostasis.<\/p>\n

Research has demonstrated Fragment 176-191’s relevance across multiple domains. In isolated adipocyte studies, the peptide demonstrated antilipogenic activity identical to intact growth hormone. In vivo studies in obese ob\/ob mice demonstrated chronic weight loss. The peptide has been shown to be more potent than full-length HGH in stimulating lipolysis.<\/p>\n

Furthermore, recent research has explored Fragment 176-191’s potential beyond metabolic regulation. A 2022 study published in Drug Design, Development and Therapy demonstrated that hGH Fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Molecular docking simulations depicted that the hGH fragment 176-191 peptide binds with high affinity to Ki-67, MiB protein, and estrogen receptor. This suggests potential research applications in oncology. Ultimately, researchers who buy Fragment 176-191 5mg in Switzerland gain access to a versatile research tool for investigating lipid metabolism, adipocyte signaling, and emerging applications in cancer research.<\/p>\n

Fragment 176-191 Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nEvidence Level<\/th>\n<\/tr>\n<\/thead>\n
Lipid Metabolism<\/td>\nLipolysis stimulation, lipogenesis inhibition, fat oxidation<\/td>\nMechanistic \/ In Vitro \/ In Vivo<\/td>\n<\/tr>\n
Adipocyte Signaling<\/td>\nFat breakdown, adipocyte function, lipid mobilization<\/td>\nMechanistic \/ In Vitro<\/td>\n<\/tr>\n
Metabolic Regulation<\/td>\nWeight regulation, obesity models, metabolic homeostasis<\/td>\nAnimal \/ Preclinical<\/td>\n<\/tr>\n
Oncology Research<\/td>\nKi-67 binding, doxorubicin enhancement, breast cancer models<\/td>\nIn Vitro<\/td>\n<\/tr>\n
Growth Hormone Biology<\/td>\nC-terminal fragment function, lipolytic domain characterization<\/td>\nMechanistic<\/td>\n<\/tr>\n
Receptor Binding Studies<\/td>\nEstrogen receptor, MiB protein, Ki-67 interactions<\/td>\nMechanistic \/ In Silico<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Fragment 176-191 Compared With Related Research Compounds<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Compound<\/th>\nResearch Focus<\/th>\nMechanism \/ Target<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
Fragment 176-191 (hGH 176-191)<\/td>\nLipid metabolism, lipolysis, metabolic regulation<\/td>\nC-terminal hGH fragment; lipolytic domain<\/td>\n16-amino acid native sequence; no human clinical trials<\/td>\n<\/tr>\n
AOD-9604<\/td>\nLipid metabolism, lipolysis, obesity research<\/td>\nModified hGH 176-191 with N-terminal Tyr substitution<\/td>\nTyrosine-modified N-terminus; improved stability; human clinical trials<\/td>\n<\/tr>\n
Full-Length hGH<\/td>\nGrowth, metabolism, IGF-1 signaling<\/td>\nGH receptor activation<\/td>\n191 amino acids; stimulates IGF-1 and growth<\/td>\n<\/tr>\n
hGH 177-191 (AOD-9401)<\/td>\nLipid metabolism, antilipogenic activity<\/td>\nC-terminal hGH fragment (177-191)<\/td>\n15-amino acid fragment; established functional context<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, Fragment 176-191 differs from AOD-9604 in its amino acid composition and research history. On the one hand, Fragment 176-191 is the native 16-amino acid C-terminal sequence (YLRIVQCRSVEGSCGF). On the other hand, AOD-9604 consists of the same core 176-191 sequence but with an N-terminal tyrosine residue substituted for the native leucine at position 176, making it a 16-residue peptide with a modified N-terminus (Tyr-hGH 177-191). This single amino acid modification was introduced to improve peptide stability and oral bioavailability. Critically, all six human clinical trials (over 890 participants total) were conducted exclusively with the AOD-9604 (tyrosine-modified) form. The unmodified HGH Fragment 176-191 has never been tested in human clinical trials.<\/p>\n

Research Applications for Fragment 176-191 in Switzerland<\/strong><\/h2>\n

Scientists have investigated Fragment 176-191 across several research domains:<\/p>\n